Parkinson’s Research News

Two of the world’s leading experts in Parkinson’s disease and Journal of Parkinson’s Disease Editors-in-Chief guided the development of this landmark supplement: Bastiaan R. Bloem, MD, PhD, Department of Neurology, Radboud University Nijmegen Medical Center, Donders Institute for Brain, Cognition and Behavior, Center of Expertise for Parkinson & Movement Disorders, Nijmegen, The Netherlands; and Patrik Brundin, MD, PhD, Center for ... read more

PD is a neurodegenerative condition for which there is currently no cure. The incidence of PD is increasing, with the number of cases expected to double worldwide by 2040. The majority of current pharmacological treatments for PD were approved for clinical use in the second half of the last century, and they only provide symptomatic relief. Derivatives of these therapies ... read more

PD is a neurodegenerative condition for which there is currently no cure. The incidence of PD is increasing, with the number of cases expected to double worldwide by 2040. The majority of current pharmacological treatments for PD were approved for clinical use in the second half of the last century, and they only provide symptomatic relief. Derivatives of these therapies ... read more

The winning papers are: Aviles-Olmos I, Dickson, J, Kefalopoulou, Z, Djamshidian, A, Kahan, J, Ell, P, Whitton, P, Wyse, R, Isaacs, T, Lees, A, Limousin, P, Foltynie, T (2014), “Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease,” J Parkinsons Dis, 4, 337–344; and Braak, H, Del Tredici, K (2017), “Neuropathological Staging of Brain Pathology in ... read more

The winning papers are: Aviles-Olmos I, Dickson, J, Kefalopoulou, Z, Djamshidian, A, Kahan, J, Ell, P, Whitton, P, Wyse, R, Isaacs, T, Lees, A, Limousin, P, Foltynie, T (2014), “Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease,” J Parkinsons Dis, 4, 337–344; and Braak, H, Del Tredici, K (2017), “Neuropathological Staging of Brain Pathology in ... read more

The winning papers are: Aviles-Olmos I, Dickson, J, Kefalopoulou, Z, Djamshidian, A, Kahan, J, Ell, P, Whitton, P, Wyse, R, Isaacs, T, Lees, A, Limousin, P, Foltynie, T (2014), “Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease,” J Parkinsons Dis, 4, 337–344; and Braak, H, Del Tredici, K (2017), “Neuropathological Staging of Brain Pathology in ... read more

According to the JCR, JPD now ranks 50th out of 271 journals in the competitive Neurosciences category. This positions the journal in top quartile of titles, up from 89th out of 267 (second quartile) last year. The annual JCR release enables the research and library communities to evaluate the world’s high-quality academic journals using a range of journal citation indicators, ... read more

According to the JCR, JPD now ranks 50th out of 271 journals in the competitive Neurosciences category. This positions the journal in top quartile of titles, up from 89th out of 267 (second quartile) last year. The annual JCR release enables the research and library communities to evaluate the world’s high-quality academic journals using a range of journal citation indicators, ... read more

According to the JCR, JPD now ranks 50th out of 271 journals in the competitive Neurosciences category. This positions the journal in top quartile of titles, up from 89th out of 267 (second quartile) last year. The annual JCR release enables the research and library communities to evaluate the world’s high-quality academic journals using a range of journal citation indicators, ... read more

“There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more

“There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more

“There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more

“There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more

“There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more

“There is clear evidence that GDNF and related growth factors can restore the dopaminergic nigrostriatal pathway in several animal models of PD,” explained lead author Roger A. Barker, PhD, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience and WT-MRC Cambridge Stem Cell Institute, Cambridge, UK. “However, this has yet to translate into a clinically meaningful and robust response in ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

The potential long-term neurological manifestations of COVID-19 infection are unknown. However, clinical symptoms like the loss of smell and taste and encephalitis suggest that the SARS-CoV-2 virus might have the ability to invade the central nervous system. “The interesting aspect of the olfactory pathway hypothesis for SARS-CoV-2 neuroinvasion is the potential presence of the virus in the brainstem, which contains ... read more

Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more

Many potential disease-modifying therapies have been identified as suitable for clinical evaluation in PD. Each potential cure for PD has to go through three clinical trial phases to test its safety, whether it shows signs of improving PD, and whether there is any meaningful benefit to people with PD. Running a clinical trial is a huge logistical, costly, and time-consuming ... read more